Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2018-02-09 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
关于续聘会计师事务所的公告
Regulatory Filings Classification · 90% confidence The document is an announcement regarding the reappointment of an accounting firm for audit services for the year 2018, including details about the audit fees for 2017. It does not contain the audit report itself or detailed financial statements, but rather a corporate announcement about the auditor engagement. The document length is short (485 characters), and it is clearly an announcement rather than a full audit report or annual report. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit work and auditor appointment, but since it is an announcement of auditor reappointment and audit fees, it is more appropriate to classify it as Regulatory Filings (RNS) because it is a regulatory announcement about audit services rather than the audit report itself.
2018-02-09 Chinese
独立董事关于会计政策变更的独立意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors regarding a change in accounting policies by 哈药集团股份有限公司. It references compliance with accounting standards and regulatory bodies but does not contain financial statements or detailed financial data. The document is short (470 characters) and serves as an independent opinion on the accounting policy change rather than a full audit report or annual report. It is not a certification letter but an independent opinion related to governance and accounting policy changes. Given the nature and length, it fits best under Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports.
2018-02-09 Chinese
八届二次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) regarding the approval of the 2017 Annual Report, Supervisory Board work report, financial decisions, profit distribution plan, asset impairment provisions, internal control reports, and accounting policy changes. It is a formal announcement of the Supervisory Board's decisions and opinions on these matters, not the full annual report itself. The document is relatively short (1164 characters) and serves as an official announcement of board resolutions related to the annual report and financial matters. Therefore, it fits best under the category of Regulatory Filings (RNS), as it does not contain the full annual report or detailed financial statements but is a regulatory announcement of supervisory board resolutions.
2018-02-09 Chinese
独立董事关于续聘会计师事务所的独立意见
Audit Report / Information Classification · 95% confidence The document is a statement from independent directors regarding the reappointment of an accounting firm for audit services for the 2018 fiscal year. It references the 2017 audit work summary report and the decision to continue with the same auditor. The document is short (501 characters) and serves as an independent opinion on the auditor reappointment rather than the audit report itself. It does not contain financial statements or detailed audit results, but rather an opinion on the auditor's qualifications and reappointment. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related audit information excluding full annual reports. Therefore, the classification is AR with high confidence.
2018-02-09 Chinese
关于修订《公司章程》的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the board of directors of 哈药集团股份有限公司 regarding amendments to the company's Articles of Association (公司章程). It details changes in registered capital and total shares, approved by the board and pending shareholder approval at the annual general meeting. The document is short (763 characters) and serves as a formal announcement of governance changes rather than the full governance report or the actual shareholder meeting materials. It does not contain financial statements or detailed governance rules but announces a governance-related update. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in company governance or board-related matters.
2018-02-09 Chinese
关于2018年日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 哈药集团股份有限公司 regarding the company's expected daily related-party transactions for the year 2018. It includes details about the nature of these transactions, amounts involved, approval procedures by the board, independent director opinions, and the impact on the company. The document is relatively short (2030 characters) and focuses on disclosure of related-party transactions rather than presenting comprehensive financial statements or detailed financial performance. It does not contain full financial data or analysis typical of an Annual Report or Interim Report. It is also not a certification, call transcript, or other specific filing type. This type of announcement fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2018-02-09 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.